Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives $45.71 Consensus Target Price from Analysts

Posted by Brian Himes on Sep 24th, 2026

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $45.7143.

A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a research note on Friday, August 14th. Morgan Stanley boosted their price target on shares of Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Wedbush reissued an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research report on Friday, August 14th. Finally, Weiss Ratings lowered shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th.

Read Our Latest Research Report on Zenas BioPharma

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $29.63 on Thursday. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. Zenas BioPharma has a 52 week low of $13.50 and a 52 week high of $44.60. The stock has a market capitalization of $1.93 billion, a PE ratio of -3.30 and a beta of -1.04. The firm has a 50 day moving average of $31.71 and a two-hundred day moving average of $25.04.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. On average, research analysts predict that Zenas BioPharma will post -5.81 EPS for the current fiscal year.

Institutional Trading of Zenas BioPharma

Several institutional investors have recently modified their holdings of the stock. Walleye Capital LLC purchased a new position in shares of Zenas BioPharma in the 2nd quarter valued at $5,306,000. NEXTBio Capital Management LP acquired a new stake in Zenas BioPharma during the 4th quarter worth $11,691,000. J. Goldman & Co LP purchased a new stake in Zenas BioPharma in the second quarter valued at $1,732,000. Bank of America Corp DE lifted its position in Zenas BioPharma by 723.5% in the first quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock valued at $7,592,000 after acquiring an additional 341,187 shares during the last quarter. Finally, EcoR1 Capital LLC acquired a new position in Zenas BioPharma in the fourth quarter valued at $28,667,000.

About Zenas BioPharma

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.